Standard MR techniques for brain imaging of multiple sclerosis (unenhanced SE or fast-SE T1-weighted and dual-echo, i.e. proton density- and T2-weighted, sequences; Gd-enhanced SE T1-weighted sequences) give important information on natural history, lesion load and inflammation in multiple sclerosis. We show here the use of special MR techniques to: detect more supratentorial lesions (fluid-attenuated-inversion-recovery); increase number and contrast-to-noise ratio, i.e. conspicuity, of enhancing lesions after Gd injection (magnetization transfer, fat saturation, image subtraction, high spatial resolution, double-triple contrast dose and delayed scan); and obtain information on myelin status (diffusion-weighting).
MillerDHGrossmanRIReingoldSC: The role of MR techniques in understanding and managing MS. Brain121: 3–24, 1998.
2.
FilippiMGrossmanRI: MRI techniques to monitor MS evolution: The present and the future. Neurology23; 58: 1147–1153, 2002.
3.
SimonJHLullJJacobsLD: A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology55: 185–192, 2000.
4.
FilippiMHorsfieldMAAderHJ: Guidelines for using quantitative measures of brain MR imaging abnormalities in monitoring the treatment of MS. Ann Neurol43: 499–506, 1998.
5.
PatyDWLiDKB: The UBC MS/MRI study group, the IFNB MS study group. Interferon beta-1b is effective in relapsing-remitting MS. MRI analysis results of a multicenter, randomised, double-blind placebo controlled trial. Neurology43: 662–667, 1993.
6.
SimonJHJacobsLDCampionM: MR studies of intramuscular interferon beta 1-a for relapsing MS. The MS collaborative research group. Ann Neurol43: 79–87, 1998.
7.
MancardiGLSardanelliFParodiRC: Effect of Copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology50: 1127–1133, 1998.
8.
ComiGFilippiMWolinskyJS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing MS. European/Canadian Glatiramer Acetate Study Group. Ann Neurol49: 290–297, 2001.
BastianelloSBozzaoAPaolilloA: Fast-SE and fast-FLAIR versus conventional SE sequences for MR quantification of MS lesions. Am J Neuroradiol18: 699–704, 1997.
11.
MehtaRCPikeGBEnzmannDR: Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. Am J Neuroradiol16: 1771–1778, 1995.
12.
FilippiMCampiADoussetV: A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology45: 478–482, 1995.
13.
LoevnerLAGrossmanRICohenJA: Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: Assessment with magnetization-transfer measurements. Radiology196: 511–515, 1995.
14.
LoevnerLAGrossmanRIMcGowanJC: Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. Am J Neuroradiol16: 1473–1479, 1995.
15.
HiehleJFJrLenkinskiREGrossmanRI: Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med32: 285–293, 1994.
16.
RenzettiPParodiRCLosaccoC: Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration. Radiol Med98: 138–143, 1999.
17.
SardanelliFIozzelliAMaiuriF: The value of chemical fat saturation pulse added to spin-echo T1-weighted sequence in evaluating Gadolinium-enhancing brain lesion in multiple sclerosis. Radiology221 (P): 134, 2001.
18.
SardanelliFLosaccoCIozzelliA: Evaluation of Gd-enhancement in brain MR of multiple sclerosis: Image subtraction with and without magnetization transfer. Eur Radiol12: 2077–2082, 2002.
19.
MolyneuxPDTubridyNParkerGJ: The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. Am J Neuroradiol19: 1715–1720, 1998.
20.
FilippiMHorsfieldMARovarisM: Intraobserver and interobserver variability in schemes for estimating volume of brain lesions on MR images in multiple sclerosis. Am J Neuroradiol19: 239–244, 1998.
21.
FilippiMRoccaMAHorsfieldMA: Increased spatial resolution using a three-dimensional T1-weighted gradient-echo MR sequence results in greater hypointense lesion volumes in multiple sclerosis. Am J Neuroradiol19: 235–238, 1998.
22.
SardanelliFParodiRCGiordanoGD: Effect of MR imaging high resolution matrix on number of detected lesions and lesion load in multiple sclerosis. Radiology205 (P): 608, 1997.
23.
WolanskyLJFindenSGChangR: Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging. Clin Imaging22: 385–392, 1998.
24.
WolanskyLJBardiniJACookSD: Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging4: 141–145, 1994.
25.
FilippiMCapraRCampiA: Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry60: 526–530, 1996.
26.
FilippiMRovarisMCapraR: A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain121: 2011–2020, 1998.
27.
SardanelliFIozzelliALosaccoC: Three subsequent single doses of Gd-chelate in brain MR of multiple sclerosis. Am J Neuroradiol24: 658–662, 2003.
28.
IannucciGRovarisMGiacomottiL: Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. Am J Neuroradiol22: 1462–1467, 2001.
29.
NusbaumAO: Diffusion tensor MR imaging of gray matter in different multiple sclerosis phenotypes. Am J Neuroradiol23: 899–900, 2002.
